תבנית:תרופה/רמיקד - Remicade: הבדלים בין גרסאות
מתוך ויקיתרופות
מ (יצירת תבנית תרופה) |
מ (יצירת תבנית תרופה) |
||
שורה 3: | שורה 3: | ||
|שם באנגלית={{{שם באנגלית|Remicade}}} | |שם באנגלית={{{שם באנגלית|Remicade}}} | ||
|מרכיב פעיל= | |מרכיב פעיל= | ||
− | {{{מרכיב פעיל|[[מרכיב פעיל::Infliximab]] 100.0 MG/VIAL {{כ}}[[ATC code 5:: | + | {{{מרכיב פעיל|[[מרכיב פעיל::Infliximab]] 100.0 MG/VIAL {{כ}}[[ATC code 5::L04AB02]]}}} |
|קבוצה פרמקולוגית (ATC)= | |קבוצה פרמקולוגית (ATC)= | ||
− | {{{קבוצה פרמקולוגית|[[ATC code 4:: | + | {{{קבוצה פרמקולוגית|[[ATC code 4:: L04AB| ]]{{ATC משרד הבריאות|L04AB|Tumor necrosis factor alpha (TNF-α) inhibitors}}}}} |
|צורת מתן={{{צורת מתן|I.V}}} | |צורת מתן={{{צורת מתן|I.V}}} | ||
|צורת מינון={{{צורת מינון|POWDER FOR CONCENTRATE FOR INFUSION}}} | |צורת מינון={{{צורת מינון|POWDER FOR CONCENTRATE FOR INFUSION}}} | ||
שורה 11: | שורה 11: | ||
|במרשם={{{במרשם|כן}}} | |במרשם={{{במרשם|כן}}} | ||
|התוויה={{{התוויה|<div style="direction:ltr;">- Adult :- Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies</div>}}} | |התוויה={{{התוויה|<div style="direction:ltr;">- Adult :- Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies</div>}}} | ||
− | |התאמת מינון={{{התאמת מינון| | + | |התאמת מינון={{{התאמת מינון|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=2}}} |
− | |התוויות נגד={{{התוויות נגד| | + | |התוויות נגד={{{התוויות נגד|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=5}}} |
− | |פרמקודינמיקה={{{פרמקודינמיקה| | + | |פרמקודינמיקה={{{פרמקודינמיקה|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=20}}} |
− | |פרמקוקינטיקה={{{פרמקוקינטיקה| | + | |פרמקוקינטיקה={{{פרמקוקינטיקה|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=31}}} |
− | |שימוש בהריון והנקה={{{שימוש בהריון והנקה| | + | |שימוש בהריון והנקה={{{שימוש בהריון והנקה|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=11}}} |
− | |תגובות בין תרופתיות={{{תגובות בין תרופתיות| | + | |תגובות בין תרופתיות={{{תגובות בין תרופתיות|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=11}}} |
− | |תופעות לוואי={{{תופעות לוואי| | + | |תופעות לוואי={{{תופעות לוואי|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=12}}} |
|שם יצרן={{{שם יצרן|[[יצרן::JANSSEN BIOLOGICS B.V, THE NETHERLAND]]}}} | |שם יצרן={{{שם יצרן|[[יצרן::JANSSEN BIOLOGICS B.V, THE NETHERLAND]]}}} | ||
|שם יצרן מקוצר=[[שם יצרן מקוצר::JANSSEN BIOLOGICS B.V, THE NETHERLAND| ]] | |שם יצרן מקוצר=[[שם יצרן מקוצר::JANSSEN BIOLOGICS B.V, THE NETHERLAND| ]] | ||
שורה 24: | שורה 24: | ||
|תאריך הגשה={{{תאריך הגשה|[[תאריך הגשה::06/2002]]}}} | |תאריך הגשה={{{תאריך הגשה|[[תאריך הגשה::06/2002]]}}} | ||
|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Remicade|רמיקד}}}}} | |קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Remicade|רמיקד}}}}} | ||
− | |עלון לרופא={{{עלון לרופא|[ | + | |עלון לרופא={{{עלון לרופא|[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf עלון לרופא]}}} |
− | |עלון לצרכן={{{עלון לצרכן|[ | + | |עלון לצרכן={{{עלון לצרכן|[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_PIL_02_03_16_app_clean_1457504249563.pdf עלון לצרכן]}}} |
− | |החמרות לעלון={{{החמרות לעלון|*[ | + | |החמרות לעלון={{{החמרות לעלון|*[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/remicade_spc_pil_Aug-2014_1408273984172.doc החמרה לעלון] |
− | *[ | + | *[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/remicade_spc_pil_Jun_2013_1371014326339.doc החמרה לעלון] |
− | *[ | + | *[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/remicade_pil_spc_worsening_Dec.13_1388390092839.doc החמרה לעלון] |
− | *[ | + | *[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_spc_pil_Dec_2012_1355378919117.doc החמרה לעלון] |
+ | *[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_100mg_injection_03_2016_FORM_1456930021135.doc החמרה לעלון]}}} | ||
|מספר רישום={{{מספר רישום|137 18 29865 05}}} | |מספר רישום={{{מספר רישום|137 18 29865 05}}} | ||
− | |תאריך עדכון=[[עדכון אחרון:: | + | |תאריך עדכון=[[עדכון אחרון::25/04/17]] |
|תמונת אריזה={{{תמונת אריזה|}}} | |תמונת אריזה={{{תמונת אריזה|}}} | ||
|שיווק הופסק={{{שיווק הופסק|לא}}} | |שיווק הופסק={{{שיווק הופסק|לא}}} |
גרסה מתאריך 18:17, 25 באפריל 2017
נתוני תרופה
במרשם
קבוצה פרמקולוגית (ATC4) | |
---|---|
מרכיב פעיל (ATC5) | Infliximab 100.0 MG/VIAL L04AB02 |
צורת מתן | I.V |
צורת מינון | POWDER FOR CONCENTRATE FOR INFUSION |
התוויה | - Adult :- Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies
|
תבנית:נתוני סל/תרופה/רמיקד - Remicade | |
התאמת מינון | Posology and method of administration |
התוויות נגד | Contraindications |
תופעות לוואי | Undesirable effects |
תגובות בין תרופתיות | Interaction with other medicinal products and other forms of interaction |
שימוש בהריון והנקה | Pregnancy and Lactation |
פרמקודינמיקה | Pharmacodynamic Properties |
פרמקוקינטיקה | Pharmacokinetic Properties |
עלון לרופא והחמרות לעלון |
עלון לצרכן | עלון לצרכן |
---|
ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
---|---|
רמיקד ® במאגר משרד הבריאות |
חיפוש מאמרים | - |
---|---|
מידע ברשת | - |
שם יצרן | JANSSEN BIOLOGICS B.V, THE NETHERLAND |
שם בעל הרישום | J-C HEALTH CARE LTD |
רישיון | תאריך הגשה: 06/2002. רישיון מתאריך: 12/2014 |
תאריך עדכון אחרון | 25/04/17 |
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
- דף התרופה: רמיקד - Remicade
- לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את:
{{תרופה/רמיקד - Remicade}}
ב:
{{תרופה/רמיקד - Remicade | שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר) }}